Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is witnessing promising advancements in its fibroblast-based therapies, particularly in preclinical settings for chronic-relapse psoriasis and bone marrow organoids aimed at cancer treatments, highlighting the potential versatility and marketability of its technology. The company is strategically improving its operational efficiency while investing in research and development, evidenced by a nine-month R&D expenditure of $6.6 million, which reflects its commitment to scaling up for clinical use and increasing manufacturing capabilities. Additionally, the broad intellectual property portfolio and focus on chronic diseases with unmet needs support a potentially advantageous position in lowering production costs and overcoming regulatory challenges, thereby enhancing the overall outlook for the company's financial future.

Bears say

FibroBiologics faces significant challenges impacting its financial outlook, including the risk of its developmental candidates failing to meet commercial revenue expectations due to market dynamics and pricing pressures. The company reported a net loss of $5.8 million for the third quarter of 2025, contributing to an over 80% decline in stock value year-to-date, contrasting sharply with a 20% increase in the Nasdaq Biotechnology Index. Additionally, rising research and development costs, driven by increased spending on CRO, cell manufacturing, and personnel, have further widened the company's losses despite efforts to implement cost efficiencies.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.